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a b s t r a c t 
Teicoplanin possesses several convenient properties for use in the delivery of outpatient parenteral an- 
timicrobial therapy (OPAT) services. However, its use is not widespread and data on its efficacy in the 
OPAT setting are limited. Here we present a case series of patients undergoing OPAT care being treated 
by either teicoplanin-based ( n = 107) or ceftriaxone-based ( n = 191) antibiotic regimens. Clinical failure 
with teicoplanin occurred in five episodes of care (4.7%) compared with only two episodes of ceftriaxone- 
based OPAT care (1.0%). Teicoplanin-associated clinical failure was observed in 2 (33.3%) of 6 patients with 
Enterococcus infections compared with 3 (3.0%) of 101 patients with non- Enterococcus infections. Overall, 
there were four (2.9%) drug-related adverse events for teicoplanin and four (1.8%) for ceftriaxone, prompt- 
ing a switch to teicoplanin in three patients. These findings support the continued use of teicoplanin in 
OPAT as well as its consideration in centres where it is not currently being offered. 
© 2020 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
Outpatient parenteral antimicrobial therapy (OPAT) services of- 
fer several advantages over conventional inpatient care, including 
reduced length of inpatient stay, improved patient satisfaction and 
cost reductions [1 , 2] . One of the challenges posed by OPAT is the 
choice of antimicrobial, needing to balance the convenience of a 
drug’s dosing interval with an appropriate safety and efficacy pro- 
file [3] . Two commonly used antimicrobial agents in OPAT are cef- 
triaxone and teicoplanin, with overlapping spectra of activity for 
Gram-positive infections, although ceftriaxone possesses no activ- 
ity against Enterococcus infections as a single agent [4] . The phar- 
macokinetics of both agents make them an attractive choice for 
OPAT as they can be administered once daily, and also three times 
weekly for teicoplanin [5] Teicoplanin displays equivalent efficacy 
with reduced nephrotoxicity compared with the other commonly 
used glycopeptide, vancomycin [6] . Although licensed in Europe 
and also being widely used in Asia and South America, teicoplanin 
is not currently approved for use in USA. Yet in the OPAT setting it 
is effective in managing skin and soft-tissue infections (SSTIs) [7] , 
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shows good outcomes for bone and joint infections (BJIs) [8] and it 
also has a role in the treatment of select cases of endocarditis [9] . 
However, some groups have reported use of OPAT teicoplanin as 
an independent risk factor for clinical failure in the management 
of infective endocarditis [10] and in SSTIs, where 25% of patients 
experienced treatment failure, and for which ceftriaxone showed 
superior clinical outcomes [3] . 
With the continued widespread use of teicoplanin in OPAT 
[4 , 11–14] , such findings compel further review of clinical outcomes 
with its use across a range of clinical conditions, particularly in 
comparison with ceftriaxone. Our centre has extensive experience 
of using teicoplanin [15] and a recent review of our service has re- 
vealed it to be the glycopeptide of choice and the second most pre- 
scribed OPAT antibiotic after ceftriaxone [13] . In the current study, 
prospectively collected data were reviewed to assess the clinical 
outcomes of teicoplanin-based regimens and, where appropriate, 
to compare with ceftriaxone-based OPAT care. 
2. Methods 
2.1. Ethics and data extraction 
Patient data, including demographics, antimicrobial(s) admin- 
istered, drug-associated adverse events (AEs) and microbiological 
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Table 1 
Teicoplanin dosing for outpatient parenteral antimicrobial ther- 
apy (OPAT) care episodes. 
Teicoplanin dose (mg) Frequency No. (%) of episodes 
801–1000 Daily 40 (37.4) 
601–800 Daily 22 (20.6) 
401–600 Daily 17 (15.9) 
400 Daily 10 (9.3) 
800–1500 ×3 weekly 15 (14.0) 
Not documented – 3 (2.8) 
investigations, were extracted from the OPAT electronic Clinical 
Infectious Diseases (elCID) database at University College London 
Hospitals (UCLH) NHS Foundation Trust [13] . Clinical records were 
anonymised at the time of data extraction. The study was approved 
by the Audit and Research Committee at the Hospital for Trop- 
ical Diseases, UCLH, who stated that as this was a retrospective 
review of routine clinical data being analysed for service develop- 
ment purposes, further formal ethical approval was not required. 
2.2. Patient cohort selection 
The case records of all patients treated by the OPAT team 
between January 2015 and February 2018 were identified. Only 
patients who received ≥3 days of teicoplanin or ceftriaxone via 
the OPAT service were considered. A total of 152 episodes of 
OPAT care that involved ≥3 days of teicoplanin administration 
were identified, but the analyses focused on the most common 
OPAT indications, namely osteomyelitis, SSTI, bacteraemia, en- 
dovascular infection and discitis, which accounted for 136 (89.5%) 
teicoplanin-based episodes (Supplementary Table S1) to allow 
comparison with ceftriaxone. A total of 31 episodes of care during 
which both teicoplanin and ceftriaxone were administered, even 
if not contemporaneously, were identified. Administration of any 
other antibiotics during the OPAT episode was not an exclusion 
criterion to enrolment in the study. Unfortunately, patient weight 
was not routinely recorded, negating display of teicoplanin dosing 
per kilogram. However, routine practice at our centre is to use 
10–12 mg/kg for endovascular infections and BJIs. In addition, ther- 
apeutic drug monitoring (TDM) is also performed for teicoplanin 
weekly, and the final doses of teicoplanin, corrected according to 
TDM if required, are described in Table 1 . 
2.3. Clinical definitions 
All patients were reviewed clinically at least weekly during an 
OPAT care episode by a multidisciplinary team including at least 
two infection specialists. The choice of antimicrobials was made 
based on clinician preference, considering multiple factors includ- 
ing microbial susceptibility data, site of infection, co-morbidities 
and drug allergy status. Outcomes were determined at the end 
of the period of intravenous (i.v.) therapy using the standard- 
ised National Outcomes Registry System (NORS) definitions ( http:// 
opatregistry.com/ ). Clinically significant drug-related AEs were de- 
fined as hospital re-admissions, change of OPAT antimicrobial drug 
owing to toxicity, or Clostridioides difficile infection. Minor changes 
in biochemical parameters or other minor AEs that did not neces- 
sitate admission or change in therapy were excluded. Re-admission 
was determined as an admission to hospital during the period of 
OPAT. 
2.4. Statistical analysis 
Continuous variables are described with the median and in- 
terquartile range (IQR). Categorical data are described as the num- 
ber and percentage. The underlying diagnosis was categorised as 
SSTI, bacteraemia, BJI or endovascular infection (including endo- 
carditis). Microbiology data were categorised regarding the pres- 
ence or absence of Staphylococcus aureus , streptococci, enterococci, 
coagulase-negative staphylococci and Gram-negative organisms. 
Given the rarity of the outcome of clinical failure, multivariable 
analysis was not performed owing to the potential for sparse data. 
3. Results 
3.1. Cohort description and exclusions 
From the clinical records in the elCID database, 107 episodes 
where the patient received teicoplanin but no ceftriaxone and 191 
episodes where the patient received ceftriaxone but no teicoplanin 
were found, which were defined as teicoplanin only-based and cef- 
triaxone only-based OPAT episodes, respectively ( Table 2 ). Patients 
received both teicoplanin and ceftriaxone of any duration during 
the clinical episode in 31 episodes ( Table 2 ); there were 3 fail- 
ures (9.7%) in these patients. One patient on teicoplanin was ad- 
mitted for a joint washout despite therapeutic levels of teicoplanin 
but then achieved cure following a further 6 weeks of teicoplanin 
monotherapy. In another patient the underlying diagnosis of os- 
teomyelitis and causative organism were never confirmed in the 
context of advanced malignancy. One other patient receiving te- 
icoplanin was admitted with Gram-negative sepsis ( Table 3 ). In 4 
of the 31 patients who received both teicoplanin and ceftriaxone 
a rash developed whilst on ceftriaxone, prompting a switch to te- 
icoplanin in 3 cases. In contrast, 1 patient developed a rash whilst 
on teicoplanin. Due to the potential confounder of receiving both 
of these antibiotics during the episode of OPAT care, these 31 were 
excluded from further analyses of clinical outcome. 
3.2. Outcomes of teicoplanin-based OPAT care 
The median age of patients receiving teicoplanin only-based 
OPAT care was 61.5 years (IQR 49–79 years) and the male to fe- 
male ratio was 1.7:1. Of the 107 patients, 15 (14.0%) also had a 
diagnosis of diabetes mellitus and 2 (1.9%) were human immun- 
odeficiency virus (HIV)-seropositive ( Table 2 ). The median dura- 
tion of teicoplanin administration was 20 days (IQR 11–35 days) 
and the mode teicoplanin dose ranged between 800 mg and 10 0 0 
mg daily ( Tables 1 and 2 ). Gram-positive bacteria were the most 
common causative organisms, although teicoplanin was also used 
in clinical episodes where Gram-negative infections were involved 
but a polymicrobial infection was suspected ( Table 2 ). Clinically 
significant teicoplanin-associated AEs were rare, occurring in only 
three episodes (2.8%) ( Table 2 ). Overall, 101 patients (94.4%) met 
the NORS definition of cure or clinical improvement and 5 patients 
(4.7%) met the definition of clinical failure ( Table 2 ). Of the clini- 
cal failures, four of the five had achieved therapeutic levels of te- 
icoplanin. Three patients were re-admitted predominantly due to 
i.v. catheter complications, one required aortic valve replacement 
following prosthetic valve endocarditis, and one patient died of 
underlying endovascular infection in the context of neutropenia 
( Table 3 ). 
3.3. Outcomes of ceftriaxone-based OPAT care 
The median age of patients receiving ceftriaxone only-based 
OPAT care was 63 years (IQR 45–75 years) and the male to fe- 
male ratio was 2.4:1. The most common indication for ceftriaxone- 
based OPAT care was SSTI, making up just over one-half (100/191; 
52.4%) of the episodes ( Table 2 ). No clinically significant AEs were 
observed in the ceftriaxone only-based cohort, although in 4 pa- 
tients who also received teicoplanin during their OPAT care episode 
a rash developed whilst on ceftriaxone. The clinical failure rate was 
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Table 2 
Indications and outcomes of teicoplanin or ceftriaxone use in outpatient parenteral antimicrobial therapy (OPAT) a . 
Teicoplanin only ( n = 107) Ceftriaxone only ( n = 191) Teicoplanin + ceftriaxone ( n = 31) 
Demographics 
Age (years) [median (IQR)] 61.5 (49–79) 63 (45–75) 67 (57.5–75.5) 
Sex (M:F) 1.7:1 2.4:1 1.8:1 
Diabetes mellitus 15 (14.0) 21 (11.0) 4 (12.9) 
HIV-seropositive 2 (1.9) 7 (3.7) 1 (3.2) 
Diagnoses 
Osteomyelitis 62 (57.9) 48 (25.1) 17 (54.8) 
Bacteraemia 18 (16.8) 0 (0) 3 (9.7) 
Endovascular infection (including endocarditis) 12 (11.2) 26 (13.6) 3 (9.7) 
SSTI 10 (9.3) 100 (52.4) 5 (16.1) 
Discitis/vertebral osteomyelitis 5 (4.7) 17 (8.9) 3 (9.7) 
Organisms identified b 
CoNS 27 (25.2) 9 (4.7) 2 (6.5) 
MSSA 23 (21.5) 58 (30.4) 11 (35.5) 
MRSA 8 (7.5) 0 (0) 1 (3.2) 
Streptococcus spp. 10 (9.3) 20 (10.5) 7 (22.6) 
Gram-negative organisms 6 (5.6) 9 (4.7) 1 (3.2) 
Enterococcus sp. 6 (5.6) 0 (0) 1 (3.2) 
Other organisms 2 (1.9) 11 (5.8) 1 (3.2) 
No organism identified 32 (29.9) 97 (50.8) 9 (29.0) 
Duration of teicoplanin use (days) 
0–2 – N/A 3 (9.7) 
3–7 17 (15.9) 11 (35.5) 
8–14 28 (26.2) 6 (19.4) 
15–21 12 (11.2) 3 (9.7) 
22–28 12 (11.2) 2 (6.5) 
≥29 38 (35.5) 6 (19.4) 
Duration of ceftriaxone use (days) 
0–2 N/A – 4 (12.9) 
3–7 90 (47.1) 11 (35.5) 
8–14 44 (23.0) 5 (16.1) 
15–21 22 (11.5) 2 (6.5) 
22–28 13 (6.8) 1 (3.2) 
≥29 22 (11.5) 8 (25.8) 
Teicoplanin-associated adverse events 
Rash 1 (0.9) N/A 1 (3.2) 
Renal impairment 2 (1.9) N/A 0 (0.0) 
Ceftriaxone-associated adverse events 
Rash N/A 0 (0.0) 4 (12.9) c 
Patient outcome 
Cure and improved 101 (94.4) 188 (98.4) 27 (87.1) 
Failure 5 (4.7) 2 (1.0) 3 (9.7) 
Not documented 1 (0.9) 1 (0.5) 1 (3.2) 
CoNS, coagulase-negative staphylococci; HIV, human immunodeficiency virus; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus ; 
MSSA, methicillin-susceptible S. aureus ; N/A, not applicable; SSTI, skin and soft-tissue infection. 
a Data are n (%) unless otherwise stated. 
b Organisms listed were identified by routine microbiological analysis. Antimicrobial drugs used included empirical choices for presumptive involvement 
of non-identified organisms. 
c In three of these patients, the rash prompted a switch to teicoplanin. 
low, with two patients (1.0%) requiring re-admission (one for i.v. 
catheter-associated complications and the other due to a stroke) 
( Table 3 ). Overall, 188 patients (98.4%) were cured or experienced 
significant improvement following the ceftriaxone-only based OPAT 
episode of care ( Table 2 ). 
3.4. Comparison between teicoplanin- and ceftriaxone-based OPAT 
care 
There was no significant difference in the age distribution 
( P = 0.397, Mann–Whitney test) or prevalence of diabetes mel- 
litus ( P = 0.44, χ2 test) between the two populations. However, 
the median (IQR) duration of ceftriaxone administration [7 (5–15) 
days] was shorter than for teicoplanin ( P < 0.0 0 01, Mann–Whitney 
test), and ceftriaxone was used more frequently than teicoplanin 
for SSTIs ( P < 0.0 0 01, χ2 test), a diagnosis for which there were no 
clinical failures throughout the cohort. In addition, ceftriaxone was 
used more frequently where no causative organism was identified 
( P = 0.018, χ2 test) as a means to ensure reasonable bacteriologi- 
cal coverage, but was never used for enterococcal infections ( Table 
2 ). These differences preclude direct comparison of the clinical fail- 
ure rates between teicoplanin- and ceftriaxone-based OPAT care, 
although this was low in both groups (4.7% and 1.0%, respectively). 
It was also notable that in the teicoplanin-only group, 2 (33.3%) 
of 6 patients with an Enterococcus infection failed OPAT therapy in 
contrast to only 3 (3.0%) of 101 with a non- Enterococcus infection 
( Table 3 ). 
4. Discussion 
Teicoplanin is an attractive antimicrobial to use in the OPAT 
setting in view of its favourable dosing regimens and safety profile 
[5 , 6] . Despite this, its use is not widespread, in part due to the 
absence of supportive clinical outcome data. Here we report a 
prospectively recorded cohort detailing our real-world experience 
of teicoplanin use in an OPAT setting. The most striking finding 
was the relatively low failure rate compared with that reported 
previously [3 , 10 , 16] . Focusing on the same clinical conditions for 
which teicoplanin was indicated, comparable clinical outcomes 
with ceftriaxone, another commonly used OPAT antimicrobial, 
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Table 3 
Characterisation of patients who failed outpatient parenteral antimicrobial therapy (OPAT) therapy a . 
Category Underlying 
diagnosis Other co-morbidity Age (years) Sex DM HIV TEC dose TEC TDM (mg/L) Organism Cause of failure Consequence of failure 
Teicoplanin only Endovascular 
infection Neutropenia secondary to 
MDS 
76 F No No 400 mg daily N/P Enterococcus 
sp. Not specified Died 
Teicoplanin only Endovascular 
infection 
(endocarditis) 
TAVI, RA, COPD 68 F No No 800 mg daily 21 Enterococcus 
sp. Medical failure for prosthetic valve 
endocarditis 
Aortic valve 
replacement 
Teicoplanin only Osteomyelitis 
(prosthetic knee 
infection) 
– 73 M Yes No 800 mg daily 23 CoNS PICC line thrombus PICC line 
removal and 
reassessment 
Teicoplanin only Osteomyelitis 
(prosthetic 
shoulder 
infection) 
JRA 28 F No No 800 mg daily 42 CoNS and 
Candida sp. Thrombophlebitis and deranged 
liver function 
Re-admission 
Teicoplanin only Osteomyelitis (left 
knee 
replacement) 
TAVI 82 M No No 1000 mg daily 28 Streptococcus 
bovis Midline thrombus and prosthetic 
valve vegetation 
Re-admission 
Teicoplanin and 
ceftriaxone Discitis/vertebral osteomyelitis – 80 M No No 1000 mg daily 34 CoNS Gram-negative sepsis Re-admission 
Teicoplanin and 
ceftriaxone Osteomyelitis (left elbow prosthetic 
infection) 
– 63 M No No 800 mg daily 33 Staphylococcus 
aureus Recurrence of elbow infection Re-admission 
Teicoplanin and 
ceftriaxone Osteomyelitis (pelvis) SCC of the penis 54 M No No 1000 mg daily 31 No organism identified Lack of clinical response with 
advanced 
malignancy 
Died 
Ceftriaxone only Osteomyelitis 
(diabetic foot) – 72 M Yes No – N/A Staphylococcus aureus Unable to tolerate i.v. catheter Re-admission 
Ceftriaxone only Endovascular 
infection 
(endocarditis) 
TAVI, AF 79 F No No – N/A Abiotrophia 
defectiva Right MCA infarct Re-admission 
AF, atrial fibrillation; CoNS, coagulase-negative staphylococci; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HIV, human immunodeficiency virus; 
i.v., intravenous; JRA, juvenile rheumatoid arthritis; MCA, middle cerebral artery; MDS, myelodysplasia; N/A, not applicable; N/P, not performed; PICC, peripherally-inserted 
central catheter; RA, rheumatoid arthritis; SCC, squamous cell carcinoma; TAVI, transcatheter aortic valve implantation. 
a Teicoplanin (TEC) dosage and therapeutic drug monitoring (TDM) indicated in the table. All patients on ceftriaxone received a dose of 2 g daily. 
were observed. These data suggest that teicoplanin is a viable 
option for OPAT. 
This study has several strengths, including the broad nature 
of the cohort and the prospective standardised data collection. 
A standardised UK NORS definition of clinical outcome in OPAT 
care was utilised, but this is limited to an assessment of outcome 
at the end of i.v. antimicrobial therapy. We were unable to ob- 
tain outcome data beyond this point, whereas previous studies as- 
sessed outcomes 1 month after the end of OPAT care [3 , 16] . Nev- 
ertheless, in these other studies, drug AEs were common (9% of 
teicoplanin-based episodes) and thus made up a sizeable propor- 
tion of causes for OPAT failure [3] , an aspect not seen in the cur- 
rent cohort. In contrast, over one-third of clinical failures in the 
current cohort were related to complications with i.v. catheters, 
in line with our previous observations that this is a significant 
source of OPAT AEs [13] . The main analysis focused on patients 
who had received either teicoplanin only- or ceftriaxone only- 
based care, but amongst patients who received both drugs signifi- 
cant AEs were seen in four patients receiving ceftriaxone, prompt- 
ing a switch to teicoplanin in three, whereas there was only one 
teicoplanin-related AE in this group. The low drug AE rate with te- 
icoplanin is unlikely to be related to dosing, as the dosing used 
in this cohort was comparable with other studies [3 , 10] where 
attained therapeutic levels did not significantly impact upon the 
rate of AEs [17] . Indeed, we routinely performed TDM for te- 
icoplanin and subtherapeutic levels were not a feature of any 
of the cases of clinical failure. Many in this cohort of patients 
had already started i.v. antimicrobials prior to admission onto the 
OPAT service, and thus early antibiotic-related AEs, occurring dur- 
ing inpatient care, may not have been documented by the OPAT 
service. 
A noticeable feature of this cohort was that osteomyelitis was 
the most common disease category treated with teicoplanin. This 
standardised category has been associated with worse OPAT out- 
comes [18] and includes joint infections both with and without 
prosthetic material. Despite this heterogeneity, the high success 
rate of OPAT care both with teicoplanin and ceftriaxone was no- 
table and further supports the treatment of these conditions by 
OPAT services, especially in the absence of suitable oral regimens 
[14 , 19] . Methicillin-resistant S. aureus (MRSA) infection has previ- 
ously been associated with OPAT failures [3] , but MRSA was rare 
in the current study. On the other hand, the current data sug- 
gest a relationship between Enterococcus infection and OPAT fail- 
ure, an observation not previously reported. Of interest, a recent 
retrospective case series found Enterococcus infection to be associ- 
ated with treatment failure for late acute prosthetic joint infections 
[20] . Evaluation of a larger cohort of patients via the national OPAT 
registry may allow a more detailed assessment of the association 
between specific organisms and clinical outcomes. 
This study has several limitations. Foremost, as mentioned 
above, data were collected on clinical outcomes only at the end of 
OPAT care as part of a standardised national reporting system and 
not longer-term than this. As relapse of the underlying infection 
can occur several weeks after ending OPAT care [16] , the true rate 
of clinical failure may have been underestimated. The majority 
of patients received additional agents before, after or alongside 
teicoplanin and ceftriaxone, and while this is reflective of real- 
world practice, it may have limited the ability to detect differences 
directly attributable to the drugs of interest, particularly when 
comparing outcomes in patients receiving both teicoplanin and 
ceftriaxone during the same clinical episode. Moreover, despite 
no evidence supporting the use of teicoplanin in the elderly or in 
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patients with diabetes, the heterogeneity in clinical conditions and 
underlying microbiological causes between the cohorts as well 
as the low rate of clinical failure limited the ability to conduct 
comparative multivariable statistical analyses of clinical outcomes. 
5. Conclusions 
Here we report a low clinical failure rate from a real-world co- 
hort of patients receiving OPAT care with teicoplanin, a safe and 
convenient antimicrobial. The data support the continued use of 
teicoplanin in OPAT and its consideration in centres where it is not 
currently being offered. 
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